Fluticasone furoate
- Generic Name
- Fluticasone furoate
- Brand Names
- Arnuity Ellipta, Avamys, Breo Ellipta, Flonase Sensimist, Trelegy Ellipta, Veramyst
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29F3O6S
- CAS Number
- 397864-44-7
- Unique Ingredient Identifier
- JS86977WNV
- Background
Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications. Fluticasone furoate was first approved in 2007.
- Indication
Fluticasone furoate is indicated for once-daily maintenance (i.e. prophylactic) treatment of asthma in patients ≥5 years old. Fluticasone furoate is available in two combination medications - one in combination with vilanterol and one in combination with both vilanterol and umeclidinium- which are both indicated for the management of chronic obstructive pulm...
- Associated Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergy, Seasonal Allergies
- Associated Therapies
- -
Medical vs Surgical Treatment in OSA Among Children
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Assaf-Harofeh Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT05651750
- Locations
- 🇮🇱
Assaf-Harofeh Medical Center, Be'er Ya'aqov, Israel
Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps.
- Conditions
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 60
- Registration Number
- NCT05143502
- Locations
- 🇪🇬
Assiut University Hospital, Assiut, Egypt
Effect of Fluticasone Furoate on Methacholine Challenge
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- University of Saskatchewan
- Target Recruit Count
- 14
- Registration Number
- NCT03898466
- Locations
- 🇨🇦
Asthma Research Lab University of Saskatchewan Room 346 Ellis Hall, Saskatoon, Saskatchewan, Canada
Effect of Health Promotion on Allergic Rhinitis by Infrared-C Ray Irradiation
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- Nanhua University
- Target Recruit Count
- 50
- Registration Number
- NCT03673384
The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma
- Conditions
- Interventions
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2018-01-29
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT03363191
Effect of Vilanterol on Methacholine Challenge Results
- Conditions
- Interventions
- First Posted Date
- 2017-10-19
- Last Posted Date
- 2018-10-11
- Lead Sponsor
- University of Saskatchewan
- Target Recruit Count
- 17
- Registration Number
- NCT03315000
- Locations
- 🇨🇦
Asthma Research Lab - University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Arnuity® Ellipta® Drug Use Investigation
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2021-04-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 336
- Registration Number
- NCT03184480
- Locations
- 🇯🇵
GSK Investigational Site, Nagasaki, Japan
Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma
- Conditions
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 425
- Registration Number
- NCT03012061
- Locations
- 🇷🇺
GSK Investigational Site, Yaroslavl, Russian Federation
Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics
- Conditions
- Interventions
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 95
- Registration Number
- NCT03002389
- Locations
- 🇺🇸
Roselove NUNOO-ASARE, Keswick, Virginia, United States
Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year
- Conditions
- Interventions
- First Posted Date
- 2016-09-07
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 477
- Registration Number
- NCT02889809
- Locations
- 🇿🇦
GSK Investigational Site, Cape Town, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.